PROCEPT BioRobotics achieved $94.5 million in Q2 revenue, representing a 19% year-over-year increase. This growth underscores the company’s strong market position and demand for its HYDROS systems, highlighting its long-term potential in the urology sector.

Key Highlights

  • PROCEPT BioRobotics reported a Q2 2026 net loss of $26.9 million, reflecting its ongoing investment in growth.
  • U.S. procedure volume increased to over 13,100, marking a 21% year-over-year rise.
  • Gross margin improved to 66% in Q2, up from 65% a year earlier, driven by higher pricing.

This surge was driven by a significant uptick in U.S. procedures, which surpassed 13,100, up approximately 21% compared to the same period in 2025. The revenue outcome also matched the consensus estimate for earnings per share (EPS) of $-0.47. With a current market cap of $1.1 billion, PRCT's financial performance demonstrates resilience despite economic challenges.

Revenue and Growth Metrics

The company’s U.S. revenue alone reached $83.4 million in Q2, reflecting growth of 20% year-over-year. Average selling prices for new HYDROS systems stood at approximately $495,000, solidifying their price position in the marketplace. Revenue from U.S. handpieces, critical for procedure execution, totaled $48.4 million, up 12% compared to last year, further enhancing the company’s earnings strategy.

By delivering 65 HYDROS systems, including 14 replacements, the company has reinforced its footprint in the urology sector.

Strategic Initiatives and Financials

PROCEPT invested heavily in innovation, leading to a gross margin of 66%, an increase from 65% in the prior year and maintaining the same margin quarter-on-quarter. Operating expenses for Q2 were $89.8 million, a notable increase from $73.9 million in Q2 2025, reflecting ongoing investments in their commercial organization and new product developments. While the company experienced a loss of $26.9 million for the quarter, up from $19.6 million the previous year, this loss aligns with its strategic focus on expanding market share through advancements in BPH treatments.

Market Performance Context

PRCT shares have experienced a 40.6% decline year-to-date, with a 52-week trading range between $16.66 and $49.90, indicating volatility within the stock. Investors should note that despite the downward pressure on the stock, the company’s consistent revenue growth and strategic positioning may offer long-term value as it navigates evolving industry demands. Upcoming catalysts, including a conference call on August 4 to discuss these quarterly results, will provide further insights into PROCEPT's strategies.

Analysis based on the Form 8-K filed 4 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.